FAM172A

Across TCGA pan-cancer cohorts, FAM172A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM172A data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher FAM172A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM172A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, KIRC, and SKCM are the cancer types where FAM172A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.052	0.688	<.001	30	view →
KIRC	DFS	Median	All	0.146	0.808	.001	12	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	6	view →
UCEC	DFS	Median	All	0.954	0.616	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM172A–BLCA (OS)

Open the BLCA breakdown →